FDA NDA · NDA022097

STAVUDINE; LAMIVUDINE; EFAVIRENZ

Sponsor: STRIDES ACROLAB

APPLICATION

NDA022097

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

STAVUDINE; LAMIVUDINE; EFAVIRENZNone (Tentative Approval)

STAVUDINE 40MG, LAMIVUDINE 150MG, EFAVIRENZ 600MG · TABLET · ORAL

2007-06-01Type 4 - New Combination · Original · priorityTA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.